Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Kahn, René S.
2018.
On the Continued Benefit of Antipsychotics After the First Episode of Schizophrenia.
American Journal of Psychiatry,
Vol. 175,
Issue. 8,
p.
712.
Schnack, Hugo
2020.
Machine Learning.
p.
307.
Kahn, René S.
2020.
On the Origins of Schizophrenia.
American Journal of Psychiatry,
Vol. 177,
Issue. 4,
p.
291.
Remington, Gary
and
Kapur, Shitij
2020.
Antipsychotics Circa 2020: What are we thinking?.
Neuropharmacology,
Vol. 175,
Issue. ,
p.
108181.
Berendsen, Steven
Van, Henricus L.
van der Paardt, Jasper W.
de Peuter, Olav R.
van Bruggen, Marion
Nusselder, Hans
Jalink, Margje
Peen, Jaap
Dekker, Jack J. M.
and
de Haan, Lieuwe
2021.
Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders.
Early Intervention in Psychiatry,
Vol. 15,
Issue. 3,
p.
669.
Gama Marques, João
and
Ouakinin, Sílvia
2021.
Schizophrenia–schizoaffective–bipolar spectra: an epistemological perspective.
CNS Spectrums,
Vol. 26,
Issue. 3,
p.
197.
Kahn, René S.
2024.
The More Things Change . . ..
American Journal of Psychiatry,
Vol. 181,
Issue. 6,
p.
474.
In their paper ‘The slow death of the concept of schizophrenia’ Guloksuz and Van Os have elegantly written about the (ir)relevance of the schizophrenia diagnosis. They make the point that this diagnosis not only carries the negative connotation of poor outcome and (hence) stigma; they also argue that schizophrenia is non-specific, showing overlap with (amongst others) bipolar disorder. How much more useful and more humane would it be, in their eyes, to focus on the more prevalent phenotype: psychosis.
There is much value, both clinically and scientifically in their proposition to study psychosis in the population, and the various component parts of this phenotype, such as hallucinations and delusions. Similarly, their statement rings true that the (ultra) high risk concept of schizophrenia, focusing on psychosis as it does, has been proven inadequate in predicting transition to schizophrenia – especially because of this limited focus and even more narrow outcome (Cannon et al. Reference Cannon, Yu, Addington, Bearden, Cadenhead, Cornblatt, Heinssen, Jeffries, Mathalon, McGlashan, Perkins, Seidman, Tsuang, Walker, Woods and Kattan2016). Indeed, in adolescence the route to psychiatric illness is broad and rather ill-defined (Mesman et al. Reference Mesman, Nolen, Reichart, Wals and Hillegers2013) providing an interesting field of research into the pathways to psychiatric illness, a field that has indeed been hampered by the aforementioned constricted definition of high-risk.
However, their main thesis that the diagnosis of schizophrenia is neither valid nor useful is not as well supported by the data as they would like to suggest. First, bipolar disorder and schizophrenia show many more differences than the response to lithium (which they cannot and do not dispute; that lithium reduces the affective symptoms of schizophrenia is of course not the same as being effective as a mono-treatment for schizophrenia, which it is not). High IQ is a risk factor for bipolar illness; in schizophrenia the risk is increased by low IQ (Maccabe et al. Reference Maccabe, Lambe, Cnattingius, Sham, David, Reichenberg, Murray and Hultman2010; Vreeker et al. Reference Vreeker, Boks, Abramovic, Verkooijen, van Bergen, Hillegers, Spijker, Hoencamp, Regeer, Riemersma-Van der Lek, Stevens, Schulte, Vonk, Hoekstra, van Beveren, Kupka, Brouwer, Bearden, MacCabe and Ophoff2016). Intracranial volume is reduced in schizophrenia (Haijma et al. Reference Haijma, Van Haren, Cahn, Koolschijn, Hulshoff Pol and Kahn2013), in bipolar illness it is increased (Hulshoff Pol et al. Reference Hulshoff Pol, van Baal, Schnack, Brans, van der Schot, Brouwer, van Haren, Lepage, Collins, Evans, Boomsma, Nolen and Kahn2012), suggesting differences in brain development between both disorders. And finally, the often-quoted genetic overlap between both disorders is smaller than the difference in genetic risk profiles, both for common and rare variants (Neale & Sklar, Reference Neale and Sklar2015). In short, schizophrenia does differentiate from bipolar disorder, clinically as well as biologically.
However, the Achilles heel in their argument is the basis on which it is founded: that schizophrenia should be understood as a form, severe or not, of psychosis. Indeed, they argue that Kraepelin's dichotomy is a false one, since psychosis is part of both schizophrenia and bipolar illness; that both disorders are cyclical and that schizophrenia can have a good outcome. All are true and uncontested. However, as they could have read, Kraepelin did not define schizophrenia on the basis of psychosis. He delineated the illness on the basis of the cognitive decline preceding the onset of psychosis – by many years. Indeed, in his original description of the illness, his account of the cognitive (and social) decline literally precedes the discussion of psychotic symptoms by many pages, indicating the relative priority – both in chronology and in relevance – he attributed to cognition rather than psychosis. Indeed, whether based on population-wide samples (Kendler et al. Reference Kendler, Ohlsson, Mezuk, Sundquist and Sundquist2016), birth cohorts (Meier et al. Reference Meier, Caspi, Reichenberg, Keefe, Fisher, Harrington, Houts, Poulton and Moffitt2014) or longitudinal high-risk studies (Seidman et al. Reference Seidman, Shapiro, Stone, Woodberry, Ronzio, Cornblatt, Addington, Bearden, Cadenhead, Cannon, Mathalon, McGlashan, Perkins, Tsuang, Walker and Woods2016), all studies show that it is the cognitive decline preceding psychosis, much more than psychotic symptoms per se, that predict the onset of schizophrenia. That is why, on the basis of these and other data, we have argued that schizophrenia should be conceptualized as a cognitive, rather than a psychotic disorder (Kahn & Keefe, Reference Kahn and Keefe2013).
In summary, Goluksuz and van Os come up short in their argument that the concept of schizophrenia is slowly dying. Yes, when viewed through the narrow prism of psychosis, schizophrenia is not unique and not a useful concept. Indeed, if psychosis it is we want to study, we should follow the lead Guloksuz and van Os provide in their paper: study the phenotype in the population in all their aspects of severity. However, if the goal is understanding, the illness that starts with cognitive and social decline – with psychosis a late (albeit prominent) symptom – we cannot do without the concept first delineated by Kraepelin. In fact, elucidating the causes and consequences of cognitive decline in psychiatric illness may not only be necessary to understand schizophrenia; it will help to differentiate this syndrome from the others it is confused with (Keefe & Kahn, Reference Keefe and Kahn2017). A need amply demonstrated by the paper of Guloksuz and van Os. The questions they raise are relevant, their proposed solutions are not.